A PHASE 1, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF SELF-AMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Self-amplifying ribonucleic acid vaccine-Pfizer (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Pfizer
- 08 Sep 2023 Status changed from active, no longer recruiting to completed.
- 17 Feb 2023 Planned End Date changed from 1 Aug 2023 to 2 Aug 2023.
- 17 Feb 2023 Planned primary completion date changed from 1 Aug 2023 to 2 Aug 2023.